IRTC - Company ID 0001388658
iRhythm Technologies, Inc. trades as IRTC and has a market capitalization of $3.82 B, making it the #1646 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $747.14M, up 26.2% from the prior year and net income of -$45.00M. This page tracks iRhythm Technologies, Inc. through 812 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-12
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years iRhythm Technologies, Inc.'s revenue grew from $64.07M to $747.14M, a compound annual growth rate of 31.4%. Net profit margin expanded from -32.6% to -6.0% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| SD | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| SCHEDULE 13G/A | - | 2026-05-08 |
| Insider trade | 4 | 2026-05-05 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
**Truist Securities MedTech Conference** on June 16, 2026, at 2:20 p.m. ET (11:20 a.m. PT)
Revenue of $199.4 million, a 25.7% increase compared to first quarter 2025
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
_Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio_ _®__ambulatory ECG devices to reduce missed arrhythmias and provide a more complete assessment of arrhythmia burden, including in post-ablation and pregnancy populations._ _1-2_
Interested parties may access a live and archived webcast of the conference call on the “Quarterly Results” section of the company’s investor website at investors.irhythmtech.com.
The largest companies sharing iRhythm Technologies, Inc.'s SEC industry classification (surgical & medical instruments & apparatus).
iRhythm Technologies, Inc. (IRTC) has a market capitalization of $3.82 B as of 2026-07-12, ranking #1646 among US-listed companies.
iRhythm Technologies, Inc. reported revenue of $747.14M for fiscal year 2025, an increase of 26.2% year over year.
In its latest fiscal year iRhythm Technologies, Inc. reported a net loss of $45.00M.